EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab By Ogkologos - April 10, 2025 598 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with relapsed and refractory multiple myeloma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable... January 15, 2025 Study Probes Awareness of Alcohol’s Link to Cancer January 18, 2023 Foodie Friday: Watermelon Fruit Pizza September 3, 2021 ASCO20 Virtual Research Round Up Podcast: Central Nervous System Tumors and... September 3, 2020 Load more HOT NEWS News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and... Into the archives: the story of HPV and cervical cancer FDA Approves Melphalan As a Liver-Directed Treatment for Uveal Melanoma High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint...
